Standards & guidance

Filter Standards and Guidance documents

Page 3 of 13

FSRH Guideline: Progestogen-only Pills (August 2022, Amended July 2023) (Evidence relocated)

17 July 2023

This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any healthcare professional or health service providing contraceptive care in the UK. In this version of the POP Guideline, the supporting evidence for the recommendations has been removed from the main text and located in an appendix for ease of reading. This document is available to FSRH members and candidates only. 

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, Amended October 2023)

13 July 2023

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of combined hormonal contraceptives (i.e. the combined oral contraceptive pill, transdermal patch and combined vaginal ring) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK. Please read this guidance document in conjunction with any relevant clinical statements for this topic: FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023) FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023) FSRH CEU Statement: New manufacturer/MHRA advice regarding nomegestrol acetate – how does this affect prescribing of Zoely®? (April 2023) FSRH CEU Statement : New advice from the MHRA regarding cyproterone acetate: how does this affect prescribing of Co-cyprindiol/Dianette® for acne/hirsutism? July 2020 FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018) FSRH CEU Statement: Oral Contraceptives and Multiple Sclerosis (March 2014) FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017) FSRH CEU Statement: Contraception and Weight Gain (August 2019) FSRH CEU Statement: Response to new reports of link between COC and Glaucoma (November 2013) The digital version can be accessed from the BMJ SRH website:  FSRH Guideline (January 2019, amended November 2020) Combined Hormonal Contraception. BMJ Sexual & Reproductive Health 2019; 45:Suppl 1.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Guidance: Combined Hormonal Contraception Quick Reference Summary (January 2019, updated October 2023)

15 June 2023

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on combined hormonal contraception (CHC). Please refer to the full 2018 FSRH CHC Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it. 

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH Guideline-related resources: Contraception After Pregnancy

20 April 2023

Additional resources supporting FSRH Guideline: Contraception After Pregnancy.

This resource is available to members/candidates of FSRH.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH Guideline-related resources: Intrauterine Contraception (March 2023)

20 April 2023

Additional resources supporting FSRH Guideline: Intrauterine Contraception

This resource is available to members/candidates of FSRH.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH CEU Guidance: Intrauterine Contraception Quick Reference Summary (April 2023)

18 April 2023

This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on intrauterine contraception. Please refer to the full 2023 FSRH Intrauterine Contraception Clinical Guideline for further information and evidence for this advice.

This resource is available to members/candidates of FSRH.

This document is up-to-date

FSRH CEU Statement: New manufacturer/MHRA advice regarding nomegestrol acetate – how does this affect prescribing of Zoely®? (April 2023)

13 April 2023

Theramex, in agreement with the MHRA, has issued a direct healthcare professional communications (DHPC) letter relating to prescribing of Zoely®, a combined oral contraceptive containing estradiol in combination with 2.5mg of the progestogen nomegestrol acetate (NOMAC). The guidance is a response to evidence indicating an association between use of preparations containing nomegestrol acetate at higher doses than in Zoely (3.75mg-5mg) and increased risk of intracranial meningioma. There is not evidence relating directly to use of Zoely itself.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

Please read this guidance document in conjunction with any relevant clinical statements for this topic.

FSRH response to new study using a mathematical model to inform dose and regimen of exogenous hormones (April 2023)

13 April 2023

A new mathematical model suggests that effective suppression of ovulation for contraception could be achieved using lower doses of progestogen and estrogen than those currently used in hormonal contraceptives. A paper published today in PLOS Computational Biology describes the model and its findings. The authors highlight that lower exposure to exogenous hormones could reduce associated health risks and side effects. The model could be used to inform dose and regimen of exogenous hormones to be investigated by future clinical trials seeking to find new options for safe, effective and acceptable contraception. Clinical trials would be required to investigate what outcomes, with such regimens, were found in practice.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH New Product Review: Intrauterine Ball (IUBTM) Ballerine® MIDI (February 2019) (Updated April 2023)

11 April 2023

Manufactured by OCON Medical Ltd, the Intrauterine Ball (IUB™) SCu300B MIDI is a copper intrauterine device (Cu-IUD) comprised of copper beads with a total exposed copper surface of 300mm² strung on a flexible Nitinol (nickel/titanium alloy), PET-coated frame. Once the IUB is released from the 3.2mm diameter insertion tube into the uterus it coils into a spherical shape measuring 15mm in diameter. Download the product review in full here.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Guidance: Switching or Starting Methods of Contraception (April 2023)

03 April 2023

This quick guide advises on effective starting or switching between contraceptive methods to reduce the risk of unplanned pregnancy. It summarises information from existing FSRH guidance documents. This guide should be used in conjunction with clinical judgment in individual situations. Published April 2023. 

This resource is available to members/candidates of FSRH.

This document is up-to-date